pharma news today glp-1 obesity drugs today Agonists Weight Loss Market Report, 2025-2030 A $60 billion industry just
Description
Participants receiving efpeglenatide more frequently achieved weight loss of 5% or 10%
It further examines actions insurers might take to benefit policyholders while maintaining a sustainable portfolio
Peripheral mechanisms contributing to osteoarthritis pain
There is a strong association between NAFLD and the metabolic syndrome with higher risk of NASH in those with underlying diabetes or obesity
Novo Nordisk, the manufacturer of Ozempic, doesnt list diverticulitis as a known side effect
Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study
